Research Center for Vitamins and Vaccines (CVIVA), Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark; Department of Clinical Epidemiology, Aarhus University, Oluf Palmes Allé 43-45, DK-8200 Aarhus N, Denmark.
Public Health Agency of Sweden, Nobels väg 18, 171 82 Solna, Sweden.
Vaccine. 2022 Mar 8;40(11):1583-1593. doi: 10.1016/j.vaccine.2021.01.028. Epub 2021 Jan 29.
In a previous cohort study of 4-year-old Danish children, revaccination with the live measles-mumps-rubella vaccine (MMR) was associated with a 16% reduction in the rate of hospitalization lasting two days or longer for non-measles-mumps-rubella infections.
To examine if the introduction of revaccination with MMR at 4 years of age in Denmark (spring 2008) and at 7-9 years of age in Sweden (autumn 2009), at a time when there was virtually no measles, mumps or rubella cases, was associated with a reduction in the rate of hospitalization-for-infection lasting two days or longer at the population level.
We included 4-year-olds in Denmark and 7-9-year-olds in Sweden. We obtained the number of hospitalization-for-infection lasting two days or longer from nationwide hospital registers. Person-years at risk were approximated from population statistics for each season and year. We performed an interrupted time series analysis using Poisson regression to estimate the change in hospitalization incidence rates following the introduction of MMR revaccination, adjusting for seasonality. We also performed analyses with control series (3-year-olds in Denmark and 4-year-olds in Sweden).
Comparing the incidence of hospitalization-for-infection lasting two days or longer after the introduction of MMR revaccination with the expected level without an introduction of MMR revaccination resulted in an incidence rate ratio of 1.07 (95% confidence interval [CI] = 0.89-1.28) for 4-year-olds in Denmark and 0.89 (95% CI = 0.77-1.02) for 7-9-year-olds in Sweden in analyses without controls. Analyses with controls gave similar results.
This population-level study of the introduction of MMR revaccination in Denmark and Sweden had inadequate power to confirm or refute the findings from an individual-level Danish study of an association between MMR revaccination and a lower incidence rate of hospitalization-for-infection lasting two days or longer.
在一项针对 4 岁丹麦儿童的队列研究中,接种活麻疹-腮腺炎-风疹疫苗(MMR)加强针与非麻疹-腮腺炎-风疹感染住院率降低 16%相关。
检测丹麦(2008 年春季)和瑞典(2009 年秋季)分别在 4 岁和 7-9 岁时接种 MMR 加强针,此时几乎没有麻疹、腮腺炎和风疹病例,是否与人群层面上因感染而住院 2 天或更长时间的比率降低有关。
我们纳入了丹麦的 4 岁儿童和瑞典的 7-9 岁儿童。我们从全国性医院登记处获取了因感染住院 2 天或更长时间的人数。风险人年数通过每个季节和年份的人口统计数据近似得到。我们采用泊松回归进行中断时间序列分析,以估计 MMR 加强针接种后住院发生率的变化,同时调整了季节性因素。我们还对控制系列(丹麦的 3 岁儿童和瑞典的 4 岁儿童)进行了分析。
与未进行 MMR 加强针接种的情况下的预期水平相比,丹麦 4 岁儿童在接种 MMR 加强针后的感染住院率为 1.07(95%置信区间 [CI]:0.89-1.28),瑞典 7-9 岁儿童为 0.89(95% CI:0.77-1.02)。无对照组的分析结果相似。
这项关于丹麦和瑞典 MMR 加强针接种的人群水平研究,其结果无法证实或反驳丹麦一项个体水平研究中关于 MMR 加强针接种与住院率降低 2 天或更长时间的感染率之间存在关联的发现,因为其研究的效力不足。